2007
DOI: 10.1016/j.heares.2006.07.003
|View full text |Cite
|
Sign up to set email alerts
|

N-Acetyl l-cysteine does not protect against premature age-related hearing loss in C57BL/6J mice: A pilot study

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
14
0

Year Published

2009
2009
2016
2016

Publication Types

Select...
4
2
1

Relationship

1
6

Authors

Journals

citations
Cited by 33 publications
(16 citation statements)
references
References 14 publications
0
14
0
Order By: Relevance
“…5g). One possible reason for such variable high frequency threshold elevation in prestin-CreER T2 –NN +/+ mice is the substantial contribution of C57BL6 strain background from the ACTG-Flpe deletor in the mixed background of prestin-CreER T2 –NN +/+ mice (Davis et al , 2007; Rodriguez et al , 2000; Spongr et al , 1997; Zheng et al , 1999). Regardless, most applications use either prestin-CreER T2 –or prestin-CreER T2 –NN +/− that all display normal hearing.…”
Section: Resultsmentioning
confidence: 99%
“…5g). One possible reason for such variable high frequency threshold elevation in prestin-CreER T2 –NN +/+ mice is the substantial contribution of C57BL6 strain background from the ACTG-Flpe deletor in the mixed background of prestin-CreER T2 –NN +/+ mice (Davis et al , 2007; Rodriguez et al , 2000; Spongr et al , 1997; Zheng et al , 1999). Regardless, most applications use either prestin-CreER T2 –or prestin-CreER T2 –NN +/− that all display normal hearing.…”
Section: Resultsmentioning
confidence: 99%
“…First, L-NAC showed no protection again age-related hearing loss in mice [14]. Blakley et al [15] reviewed differences between species highlighting the differences in ototoxic dose for gentamicin and cisplatin between mice and guinea pigs.…”
Section: Discussionmentioning
confidence: 99%
“…Yet it has not been utilized successfully in protection against ARHL in either the C57BL/6J mouse (Davis et al, 2007) or the F344/NHsd rat (Bielefeld et al, 2008). It must be noted, though, that unsuccessful studies of pharmacological protection from acquired hearing loss are complicated by numerous factors related to dosing levels, frequency of dosing, etc, and do not extinguish the possibility that a particular drug (in this case, L-NAC) can be used as a successful prevention against ARHL.…”
Section: Strategies For Preventing or Treating Arhlmentioning
confidence: 99%